Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
received:
26
07
2021
accepted:
03
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002-2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASR
Identifiants
pubmed: 35013373
doi: 10.1038/s41598-021-03734-6
pii: 10.1038/s41598-021-03734-6
pmc: PMC8748501
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
323Informations de copyright
© 2022. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724–3734 (2010).
pubmed: 20664057
doi: 10.1182/blood-2010-05-282632
Jaffe, E. S., Harris, N. L., Stein, H. & Wardiman, J. W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2001).
Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2008).
Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, 2017).
Sant, M., Karjalainen-Lindsberg, M. L., Maynadié, M., & HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori 96(4), (2010).
Fritz, A. et al. International Classification of Diseases for Oncology 3rd edn, 357 (World Health Organization, 2000).
Visser, O. et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur. J. Cancer 48, 3257–3266 (2012).
pubmed: 22770878
doi: 10.1016/j.ejca.2012.05.024
Srour, S. A. et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br. J. Haematol. 174, 382–396 (2016).
pubmed: 27061824
pmcid: 4961550
doi: 10.1111/bjh.14061
Ma, X., Does, M., Raza, A. & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536–1542 (2007).
pubmed: 17345612
doi: 10.1002/cncr.22570
Rollison, D. E. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112, 45–52 (2008).
pubmed: 18443215
doi: 10.1182/blood-2008-01-134858
Bailey, C. et al. Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995–2009. Cancer 124, 3856–3867 (2018).
pubmed: 30343495
doi: 10.1002/cncr.31674
Maynadié, M. et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica 96, 55–61 (2011).
pubmed: 20971817
doi: 10.3324/haematol.2010.026252
Roman, E. et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15. Cancer Epidemiol. 42, 186–198 (2016).
pubmed: 27090942
pmcid: 4911595
doi: 10.1016/j.canep.2016.03.011
Osca-Gelis, G. et al. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 98, e95–e97 (2013).
pubmed: 23812933
pmcid: 3729892
doi: 10.3324/haematol.2013.084061
Navarro, C. et al. Population-based cancer registries in Spain and their role in cancer control. Ann. Oncol. 21, 3–13 (2010).
doi: 10.1093/annonc/mdq094
Spanish Network of Cancer Registries (REDECAN). Available at: https://stage.redecan.org/es . (Accessed: 17th March 2021)
Instituto Nacional de Estadística (INE) [Available at: https://www.ine.es , last accessed on April 16, 2020].
World Health Organization. International classification of diseases for oncology (ICD-O) – 3rd edition, 1st revision, 3rd ed.; 2013. Available at: https://apps.who.int/iris/handle/10665/96612 .
Maynadié, M. et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 98, 230–238 (2013).
pubmed: 22983589
pmcid: 3561430
doi: 10.3324/haematol.2012.064014
Gavin, A. et al. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. Eur. J. Cancer 51, 1109–1122 (2015).
pubmed: 24630945
doi: 10.1016/j.ejca.2014.02.008
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2020. Available at: https://www.R-project.org/ .
Marcos-Gragera, R. et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: Results of the HAEMACARE project. Haematologica 96, 720–728 (2011).
pubmed: 21330324
pmcid: 3084919
doi: 10.3324/haematol.2010.034264
Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).
pubmed: 15781101
doi: 10.1016/S0140-6736(05)71142-9
Polednak, A. P. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries. J. Registry Manag. 41, 77–84 (2014).
pubmed: 25153013
Derolf, Å. R. et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 113, 3666–3672 (2009).
pubmed: 19020306
doi: 10.1182/blood-2008-09-179341
Broccia, G. et al. Hematological malignancies in the island of Sardinia, 1974–1993: age and sex distributions and temporal changes in incidence. Hematol. Oncol. 22, 91–109 (2004).
pubmed: 15991220
doi: 10.1002/hon.733
Smith, A., Howell, D., Patmore, R., Jack, A. & Roman, E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br. J. Cancer 105, 1684–1692 (2011).
pubmed: 22045184
pmcid: 3242607
doi: 10.1038/bjc.2011.450
Ghazawi, F. M. et al. Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario. Cancer 125, 1886–1897 (2019).
pubmed: 30811592
doi: 10.1002/cncr.32034
Schnegg-Kaufmann, A. et al. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiol. 52, 55–62 (2018).
pubmed: 29223104
doi: 10.1016/j.canep.2017.11.008
Sanderson, R. N. et al. Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia. Leukemia 20, 444–450 (2006).
pubmed: 16424877
doi: 10.1038/sj.leu.2404055
Bacher, U. et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 90, 1502–1510 (2005).
pubmed: 16266897
Preiss, B. S. et al. Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. Br. J. Haematol. 123, 219–234 (2003).
pubmed: 14531903
doi: 10.1046/j.1365-2141.2003.04568.x
Dinmohamed, A. G. & Visser, O. Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem cell Investig. 6, 37 (2019).
pubmed: 31853453
pmcid: 6917547
doi: 10.21037/sci.2019.10.03
Girodon, F. et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 94, 865–869 (2009).
pubmed: 19377078
pmcid: 2688580
doi: 10.3324/haematol.2008.004234
Reedijk, A. M. J. et al. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia 33, 1349–1359 (2019).
pubmed: 30568171
doi: 10.1038/s41375-018-0314-7
Arber, D. A. et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Sweeney, M. R. et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol. Biomarkers Prev. 28, 1502–1517 (2019).
pubmed: 31213463
doi: 10.1158/1055-9965.EPI-19-0106
Duncombe, A. S. et al. Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. HemaSphere 4, e327 (2020).
pubmed: 32072143
pmcid: 7000482
doi: 10.1097/HS9.0000000000000327
Taylor, J., Xiao, W. & Abdel-Wahab, O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 130, 410–423 (2017).
pubmed: 28600336
pmcid: 5533199
doi: 10.1182/blood-2017-02-734541
Craig, B. M., Rollison, D. E., List, A. F. & Cogle, C. R. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol. Biomarkers Prev. 21, 474–481 (2012).
pubmed: 22237987
pmcid: 3662977
doi: 10.1158/1055-9965.EPI-11-1087
Cogle, C. R., Craig, B. M., Rollison, D. E. & List, A. F. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117, 7121–7125 (2011).
pubmed: 21531980
pmcid: 3143554
doi: 10.1182/blood-2011-02-337964
Dinmohamed, A. G. et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk. Res. 39, 177–182 (2015).
pubmed: 25533930
doi: 10.1016/j.leukres.2014.11.025
McQuilten, Z. K. et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120, 1686–1694 (2014).
pubmed: 24643720
doi: 10.1002/cncr.28641
Solans, M. et al. Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain. Cancer Causes Control 29, 379–382 (2018).
pubmed: 29383469
doi: 10.1007/s10552-018-1004-5
Monnereau, A. et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int. J. cancer 132, 2378–2387 (2013).
pubmed: 23034773
doi: 10.1002/ijc.27889
International Agency for Cancer Registration (IACR). International Classification of Diseases for Oncology. ICD-O-3.2. (2021). Available at: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577 . (Accessed: 3rd March 2021).
Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
pubmed: 33024307
doi: 10.1038/s41579-020-00459-7
Petrova, D., Pérez-Gómez, B., Pollán, M. & Sánchez, M.-J. Implications of the COVID-19 pandemic for cancer in Spain. Med. Clin. (Barc) 155, 263–266 (2020).
doi: 10.1016/j.medcli.2020.04.011
Maringe, C. et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 21, 1023–1034 (2020).
pubmed: 32702310
pmcid: 7417808
doi: 10.1016/S1470-2045(20)30388-0
Steensma, D. P. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr. Hematol. Malig. Rep. 7, 310–320 (2012).
pubmed: 23015360
doi: 10.1007/s11899-012-0140-3
Parmentier, S. et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica 97, 723–730 (2012).
pubmed: 22180437
pmcid: 3342975
doi: 10.3324/haematol.2011.056879